Conclusion
Eptifibatide maintenance dose infusion in patients who undergo PPCI in
the context of STEMI, does not significantly reduce MACE, although it
does significantly reduce re-hospitalization, re-infarction and TLR. It
also does not increase the risk of bleeding and cerebrovascular
events.